REZENOPY, Highest-Dose Naloxone Nasal Spray, Enters U.S. Market

Scienture Holdings announced Thursday that it has completed manufacturing of commercial launch inventory for REZENOPY and will begin shipments to U.S. pharmaceutical wholesalers later this month, with the medication expected to reach pharmacies and healthcare providers by August. The 10-milligram naloxone hydrochloride nasal spray represents the highest-dose FDA-approved overdose reversal medication available in the United States—more than double the 4mg formulations currently dominating the market.

What makes REZENOPY different

REZENOPY delivers 10mg of naloxone in a single-use nasal spray device, compared to the 4mg doses found in Narcan, RiVive, and Rextovy. The FDA approved REZENOPY on April 19, 2024, but the product required time to establish manufacturing partnerships and distribution infrastructure before reaching patients.

Scienture entered into an exclusive U.S. commercialization agreement with Summit Therapeutics, a Kindeva subsidiary, in March 2025. Under the terms, Summit manufactures and supplies the product while Scienture handles commercialization and distribution.

The higher dose addresses a growing concern among emergency responders and addiction medicine specialists: the increasing potency of illicit opioids circulating in American communities. As fentanyl analogues and other synthetic compounds have grown stronger, some medical professionals have questioned whether standard 4mg doses always provide sufficient reversal, particularly for individuals with high opioid tolerance or when multiple substances are involved.

Market context and competition

The U.S. naloxone market generates approximately $144 million in annual sales across roughly 9.8 million units, according to Scienture's market analysis. REZENOPY enters a field that has expanded significantly in recent years as regulators and public health officials have worked to make overdose reversal medication more accessible.

Narcan became available over-the-counter in 2023, followed by RiVive and Rextovy in 2024 and 2026 respectively. All three competing products deliver 4mg doses. REZENOPY's 10mg formulation distinguishes it as a higher-potency option, though medical experts caution that dose selection should follow clinical guidelines rather than assuming higher is always better.

The product's arrival coincides with encouraging national trends. The Centers for Disease Control and Prevention reported a 14% decline in drug overdose deaths for 2025—the third consecutive year of decreasing mortality. Fentanyl remains the primary driver of overdose fatalities, involved in the majority of deaths, but expanded naloxone distribution, medication-assisted treatment access, and harm reduction programs have contributed to the mortality reduction.

Clinical considerations

Naloxone works by binding to opioid receptors in the brain, displacing opioid molecules and temporarily reversing their effects. The medication can restore normal breathing within minutes when administered during an overdose involving opioids including fentanyl, heroin, and prescription pain medications.

Higher-dose formulations may offer advantages in specific clinical scenarios, such as overdoses involving potent synthetic opioids or cases requiring multiple administrations. However, medical professionals note that naloxone also precipitates withdrawal symptoms in opioid-dependent individuals, and higher doses can potentially trigger more severe withdrawal reactions.

The American Society of Addiction Medicine and other professional organizations maintain clinical guidelines for naloxone administration, emphasizing that proper training in recognizing overdose signs and administering the medication matters as much as the specific product chosen.

Distribution and access

Scienture expects REZENOPY to become commercially available in August 2026 through wholesale pharmaceutical distributors. The company has not yet announced pricing or whether it will pursue over-the-counter status, which would make the product available without a prescription at pharmacies and retail locations.

Currently, all three competing naloxone nasal sprays hold OTC approvals, a regulatory shift that has dramatically expanded community access. Prescription naloxone products remain available for patients whose insurance requires a prescription for coverage.

Community organizations, first responder agencies, and harm reduction programs represent significant distribution channels for naloxone products. Many such programs receive funding through opioid settlement dollars or federal grants to provide free naloxone to individuals at risk of overdose and their family members.

The evolving overdose landscape

REZENOPY's market entry arrives during a complex period in the American overdose crisis. While overall deaths have declined, new challenges have emerged. The veterinary sedative medetomidine—100 to 200 times more potent than xylazine—has increasingly contaminated the fentanyl supply, creating naloxone-resistant overdoses that require additional medical interventions beyond opioid reversal.

Public health officials emphasize that naloxone remains essential for responding to opioid-involved overdoses, which still comprise the majority of fatalities. However, the changing drug supply underscores the need for comprehensive approaches that include not just overdose reversal medications but also expanded treatment access, harm reduction services, and addressing the social determinants that drive substance use.

Scienture's announcement highlights how pharmaceutical innovation continues alongside public health interventions in addressing the overdose crisis. Whether REZENOPY's higher-dose formulation becomes a preferred option for specific clinical situations will depend on real-world experience, cost considerations, and prescriber preferences as the product becomes available nationwide.